Britannia Pharmaceuticals: Landmark Apomorphine Study Confirms its Established Role as a Highly Effective Treatment for Parkinson#s Disease Patients Whose Symptoms Cannot be Controlled on Standard Therapies

Food and Healthcare Press Releases Wednesday April 26, 2017 08:06
READING, England--26 Apr--PRNewswire/InfoQuest

Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go(R)/MOVAPO(R) (apomorphine) subcutaneous infusion in Parkinson's disease (PD) patients whose motor symptoms are not controlled by other therapies - the TOLEDO study - were presented during the 'Emerging Science' session at the American Academy of Neurology (AAN) Annual Meeting in Boston, USA, on 25th April 2017. The session highlighted the best neuroscientific research at the congress.

Although APO-go(R)/MOVAPO(R) infusion has been used successfully in clinical practice for almost 30 years in Europe and many uncontrolled studies have shown its benefits in decreasing 'off' time, improving dyskinesias and reducing the need to take oral levodopa, to date these observations have not been confirmed in the setting of a controlled clinical trial.

Professor Katzenschlager, the lead investigator of TOLEDO, presented the results of the 12-week, double-blind phase undertaken in 107 patients from 23 centres around Europe. Patients treated with APO-go(R)/MOVAPO(R) infusion had a significantly greater improvement in 'off' time from baseline to Week 12 compared with those on placebo, resulting in a difference between treatments of almost 2 hours. The effect of APO-go(R)/MOVAPO(R) was rapid: a reduction in 'off' time was observed at the first assessment at Week 1 and was sustained over the 12 weeks of the study. Importantly, this clinically meaningful reduction in 'off' time was achieved without an increase in dyskinesias and was reflected in the patients' own assessment of the overall treatment effect.

Professor Katzenschlager commented: "TOLEDO provides the high-level evidence we needed for the efficacy and tolerability of apomorphine infusion in patients who are still experiencing debilitating treatment response fluctuations despite receiving optimized treatment, and confirms the clinical experience of those who have used apomorphine infusion for many years. The trial also gives us a 'tried and tested' initiation protocol that clinicians can follow and adapt to their own clinical setting. The impressive results should give them added confidence to prescribe this valuable but underused therapy."

The TOLEDO study is sponsored by Britannia Pharmaceuticals Ltd., part of the STADA Arzneimittel AG group of companies and manufacturer of apomorphine products (APO-go(R) /MOVAPO(R)/APOKYN(R)). The open-label phase of TOLEDO is ongoing and results are expected in 2018.

Reference
Katzenschlager R, et al. Poster 003 presented at the 69th American Academy of Neurology Annual Meeting, Boston, MA, USA, 22-28 April 2017.
Background:

Founded in 1982, Britannia Pharmaceuticals Limited is a pharmaceutical company based in Reading, UK, specialising in the neurology market. The company's primary expertise is in the development and marketing of products in the area of PD. Working closely for over 30 years with neurologists and geriatricians, Britannia identified the benefit of and need for apomorphine as a treatment for PD, which led to the development of APO-go(R)/MOVAPO(R) /APOKYN(R) products. The product is available in 23 countries round the world.

Britannia is owned by Frankfurt-based STADA Arzneimittel AG. APO-go(R) is amongst the TOP 5 branded products of the STADA Group.

APO-go(R) products are marketed in the UK by Britannia Pharmaceuticals Ltd and transferred with the acquisition of Britannia into the STADA portfolio in 2007. APO-go(R) products are marketed outside the UK through own affiliates and licensing partners.

For further information contact at Britannia Pharmaceutical Ltd:
Medical Information at Britannia Pharmaceutical Ltd
http://www.britannia-pharm.com
PIL:   https://www.medicines.org.uk/emc/medicine/15993 .
Source: Britannia Pharmaceuticals Ltd

Latest Press Release

Novo Nordisk (Thailand) is hosting a press conference for the topic of Rethink Obesity.

Mr. John Dawber, Vice President and General Manager at Novo Nordisk (Thailand) is hosting a press conference for the topic of "Rethink Obesity". The event will be chaired by His Excellency Mr. Uffe Wolffhechel, Ambassador of Denmark to Thailand, and will...

Brain Health Supplements Market Expecting an Outstanding Growth Till 2025

The global brain health supplements market size is expected to reach USD 10.7 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.2% over the forecast period. Growing health concerns over depression, anxiety,...

Menarini Silicon Biosystems Launches VRNxT Volume Reduction Instrument

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, announced that it will launch the new VRNxT(TM), a volume reduction instrument optimized to remove manual sample volume reduction steps in cellular biology...

BREASTFEEDING CAMPAIGN SETS A NEW REGIONAL STANDARD FOR SUSTAINABLE COMMUNICATION

The "6 months mother's milk is all you need" campaign has been awarded South East Asia PR Campaign of the year and Cause related public awareness campaign of the Year by Campaign Asia at the PR awards in Hong Kong last month. Initiated by Save The...

Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of NABOTA

Daewoong Pharmaceutical Co., Ltd, a world-leading botulinum toxin manufacturer in Korea, announced its participation in IMCAS Asia 2019 held in Bali, Indonesia July 5-7, 2019 to introduce the excellence of NABOTA(R) (Prabotulinumtoxin A). The 13th year...

Related Topics